While impairments attributed to leptin genetic mutations are treatable with recombinant methionyl human leptin administration, as result of leptin resistance replacement therapy in individuals with obesity does not provide therapeutic benefit. The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.